Protalix Biotherapeutics inc   (PLX)
Other Ticker:  
Price: $1.4500 $0.02 1.399%
Day's High: $1.5 Week Perf: -1.36 %
Day's Low: $ 1.43 30 Day Perf: -1.36 %
Volume (M): 270 52 Wk High: $ 3.55
Volume (M$): $ 392 52 Wk Avg: $1.87
Open: $1.44 52 Wk Low: $1.21

 Market Capitalization (Millions $) 121
 Shares Outstanding (Millions) 84
 Employees -
 Revenues (TTM) (Millions $) 64
 Net Income (TTM) (Millions $) 11
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 1

Protalix Biotherapeutics Inc
Protalix Biotherapeutics Inc. is a biopharmaceutical company based in Israel. It specializes in the development and commercialization of recombinant therapeutic proteins for the treatment of various diseases. The company focuses on utilizing its proprietary plant cell-based protein expression system, ProCellEx', to produce a wide range of protein-based therapeutics.

Protalix's ProCellEx technology offers advantages over traditional production methods, as it enables the efficient production of complex proteins with enhanced stability and bioactivity. This innovative platform has been used to develop and manufacture several FDA-approved products, including Elelyso' (taliglucerase alfa) for the treatment of Gaucher disease.

The company's pipeline includes other promising product candidates targeting different medical conditions, such as Fabry disease, cystic fibrosis, and immune-mediated disorders. Protalix also collaborates with other pharmaceutical companies and researchers to broaden its therapeutic capabilities and explore new applications for its technology.

In addition to its focus on product development, Protalix Biotherapeutics places great emphasis on ensuring patients' access to its treatments. The company actively engages in reimbursement negotiations and collaborations with healthcare providers to facilitate widespread availability and affordability of its therapies.

Overall, Protalix Biotherapeutics Inc. is a biopharmaceutical company that utilizes its ProCellEx technology to develop and commercialize recombinant therapeutic proteins, with the ultimate goal of improving patients' lives by addressing various medical needs.

   Company Address: 2 University Plaza Hackensack 7601 NJ
   Company Phone Number: 696-9345   Stock Exchange / Ticker: NYSEAMER PLX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Protalix Biotherapeutics Inc

Protalix Biotherapeutics Inc's Fiscal Q3 2023 Revenue Takes a Grim -27.061% Hit: Understanding the Factors Behind the Drop

Declining Business Leads to Increase in Shortfall for Protalix Biotherapeutics Inc in Q3 2023
Protalix Biotherapeutics Inc, a leading biopharmaceutical company, experienced declining business in the fiscal third quarter of 2023, resulting in an increase in the company's shortfall. The shortfall per share rose to $-0.04 from $-0.07, indicating a challenging period for the company.
One of the key factors contributing to the increased shortfall was a significant drop in revenue. The company's revenue decreased by -27.061% to $10.35 million from $14.18 million a year ago. This decline can be attributed to various factors such as changes in market dynamics, competition, or even external economic conditions. In comparison to the previous quarter, the revenue tumbled even further by -70.506% from $35.08 million.

Protalix Biotherapeutics Inc

Protalix Biotherapeutics Inc's Second Quarter Revenue Skyrockets, Stands Out in Biotechnology & Pharmaceuticals Sector!

As a stock market journalist, I have been analyzing the financial results of Protalix Biotherapeutics Inc, and I must say that the numbers are quite impressive. The company's revenue saw a remarkable increase of 300.72% year on year, reaching $35.08 million in the three months ending June 30, 2023. This significant revenue surge is bucking the trend in the Biotechnology & Pharmaceuticals sector, where most of the company's peers experienced business contraction during the same period.
Not only did Protalix Biotherapeutics Inc witness a substantial increase in revenue, but its earnings per share (EPS) also turned positive, reaching $0.21. This is a significant improvement from the previous quarter, where the company reported an EPS of -$0.05 per share. Additionally, the company's revenue doubled by 265.822% quarter on quarter, rising from $9.59 million.

Protalix Biotherapeutics Inc

Protalix Biotherapeutics Inc Reports $0.05 Loss per Share in Latest Fiscal Period

Investors in Protalix Biotherapeutics Inc were left disappointed with the company's most recent fiscal period as the biotechnology and pharmaceuticals company reported a -40.392% revenue decrease to $9.59 million. The company also posted a net loss of $-0.05 per share in the first quarter of 2022, which is proportional to $-0.05.
Although earnings per share improved from $-0.07 and revenue advanced by 11.268% from $8.62 million in the prior reporting period, the most recent fiscal period realized a net loss of $-3.131 million, which is higher than the $-2.286 million recorded a year ago.


Protalix Biotherapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com